These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
978 related articles for article (PubMed ID: 28063134)
1. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134 [TBL] [Abstract][Full Text] [Related]
2. [Risk sharing methods in middle income countries]. Inotai A; Kaló Z Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986 [TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. Hu J; Mossialos E Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345 [TBL] [Abstract][Full Text] [Related]
4. Drug Policy in Romania. Radu CP; Pana BC; Furtunescu FL Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726 [TBL] [Abstract][Full Text] [Related]
5. Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). Pani L; Montilla S; Németh G; Russo P; Viceconte G; Vogler S Pharmacol Res; 2016 Sep; 111():247-250. PubMed ID: 27293051 [No Abstract] [Full Text] [Related]
6. Price comparison of high-cost originator medicines in European countries. Vogler S; Zimmermann N; Babar ZU Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050 [TBL] [Abstract][Full Text] [Related]
7. Prices of new medicines: International analysis and policy options. Vogler S Z Evid Fortbild Qual Gesundhwes; 2022 Dec; 175():96-102. PubMed ID: 36372642 [TBL] [Abstract][Full Text] [Related]
8. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis. Son KB Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820 [TBL] [Abstract][Full Text] [Related]
9. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways. Inotai A; Kaló Z Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392 [No Abstract] [Full Text] [Related]
10. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines? Vogler S; Salcher-Konrad M; Habimana K Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611 [TBL] [Abstract][Full Text] [Related]
11. Drug Policy in Hungary. Inotai A; Csanádi M; Harsányi A; Németh B Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982 [TBL] [Abstract][Full Text] [Related]
12. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare. Critchley GJ; Zaric GS Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424 [TBL] [Abstract][Full Text] [Related]
13. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies]. Castillo-Laborde C; Silva-Illanes N Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178 [TBL] [Abstract][Full Text] [Related]
14. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs). Babar ZU Res Social Adm Pharm; 2024 Sep; 20(9):934-939. PubMed ID: 38908991 [TBL] [Abstract][Full Text] [Related]
15. The enigma of value: in search of affordable and accessible health care. Szucs TD; Weiss M; Klaus G Eur J Health Econ; 2017 Jul; 18(6):667-670. PubMed ID: 27913941 [TBL] [Abstract][Full Text] [Related]
16. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience. Dunlop WCN; Staufer A; Levy P; Edwards GJ Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205 [TBL] [Abstract][Full Text] [Related]
17. Differences in external price referencing in Europe: a descriptive overview. Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843 [TBL] [Abstract][Full Text] [Related]
18. Managed Entry Agreements: Policy Analysis From the European Perspective. Dabbous M; Chachoua L; Caban A; Toumi M Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159 [TBL] [Abstract][Full Text] [Related]
19. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage. Holtorf AP; Gialama F; Wijaya KE; Kaló Z Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014 [TBL] [Abstract][Full Text] [Related]